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Abstract
Background: Oral menopausal hormone therapy causes venous thrombosis but 
whether biomarkers of thrombosis risk can identify women at risk is unknown.
Methods: We completed a nested case control study in the two Women’s Health 
Initiative hormone trials; 27 347 women aged 50- 79 were randomized to hormone 
therapy (conjugated equine estrogen with or without medroxyprogesterone acetate) 
or placebo. With 4 years follow- up, biomarkers were measured using stored baseline 
samples prior to starting treatment, and one- year later, in 215 women who devel-
oped thrombosis and 867 controls.
Results: Overall, lower protein C and free protein S, and higher D- dimer, prothrombin 
fragment 1.2 and plasmin- antiplasmin complex were associated with risk of future 
thrombosis with odds ratios ranging from 1.9 to 3.2. Compared to women with nor-
mal biomarkers assigned to placebo, the risk of thrombosis with hormone therapy 
was increased among women with abnormal biomarkers, especially elevated 
D- dimer, elevated plasmin- antiplasmin, and low free protein S; the largest association 
was for D- dimer: odds ratio 6.0 (95% CI 3.6- 9.8). Differences in associations by 
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1  | INTRODUC TION
Oral menopausal hormone therapy (HT) increases the risk of venous 
thrombosis (VT).1,2 As this treatment provides effective relief of 
menopausal symptoms and VT is the most common adverse vascu-
lar outcome of HT, knowledge of susceptibility factors might assist 
women and their physicians in decision- making on risks and benefits 
of HT use.
In perimenopausal women, the annual rate of VT is 1- 2 per 1000,3 
which rises to 0.5- 1% over 5 years of HT use. In the Women’s Health 
Initiative (WHI) trials women who were older, obese, or had factor V 
Leiden were at higher risk of VT with HT.1,2 For example, conjugated 
equine estrogens plus medroxyprogesterone acetate (E+P) doubled 
the risk of VT overall but in women with factor V Leiden the risk was 
increased 6.7- fold, predicting a cumulative incidence of 3.3- 6.7% 
over 5 years of HT use. Other hemostatic disorders associated with 
VT risk might predict susceptibility for HT- related VT, as might HT- 
induced changes in hemostasis or inflammation factors.4–7 We hy-
pothesized that levels of hemostasis factors and C- reactive protein 
(CRP), an inflammation marker, would be associated with risk of VT 
with HT in the WHI trials, and that changes in some of these factors 
while on treatment would be associated with increased risk of VT.
We conducted a case- control study nested in the two WHI hor-
mone trials. We measured biomarkers of thrombosis risk (factors 
VIIc, VIIIc, and IXc, von Willebrand factor, fibrinogen, protein C, 
protein S, antithrombin, prothrombin, D- dimer, and CRP) and others 
that are altered by HT but have no or uncertain associations with 
VT (plasminogen activator inhibitor- 1 [PAI- 1], prothrombin fragment 
1.2, plasmin antiplasmin complex [PAP]). Associations of one- year 
HT- induced changes in some of these biomarkers with risk of VT 
were also studied.
2  | METHODS
The study design was a nested case control study embedded in two 
randomized controlled trials of hormone use versus placebo (clini-
caltrials.gov identifier NCT 00000611; Women’s Health Initiative).
2.1 | Subjects
Detailed descriptions and results of the WHI hormone trials, in-
cluding Consolidated Standards of Reporting Trials diagrams, were 
previously published.8–11 Eligible postmenopausal women aged 50- 
79 years were enrolled in 1993- 1998. Exclusion criteria related to 
safety concerns with HT. Methods were approved at each site by 
institutional review committees, and participants provided written 
informed consent.
The WHI hormone trials included 16 608 women with an in-
tact uterus who were randomly assigned in double- blind fashion 
to receive E + P or identical placebo, and 10 739 women without a 
uterus who were randomized to E or placebo. Treatment included 
one daily tablet containing 0.625 mg conjugated equine estrogen 
with or without 2.5 mg medroxyprogesterone acetate or identical 
placebo. At baseline and one year later, blood was drawn and stored 
at −70 °C.
hormone use were not significant on the multiplicative scale. Considering a multi- 
marker score of eight biomarkers, women with three or more abnormal biomarkers 
had 15.5- fold increased odds of VT (95% CI 6.8- 35.1). One- year changes in biomark-
ers were not robustly associated with subsequent thrombosis risk.
Conclusion: Abnormal levels of biomarkers of thrombosis risk identified women at 
increased risk of future venous thrombosis with oral menopausal hormone therapy. 
Findings support the potential for clinical use of D- dimer testing in advance of hor-
mone therapy prescription.
K E Y W O R D S
blood coagulation, D-dimer, menopausal hormone therapy, risk assessment, risk factor, 
venous thrombosis, venous thromboembolism
Essentials
● Venous thrombosis is the most common vascular complication of menopausal hormone use.
● We studied biomarkers to predict thrombosis with hormones in the Women’s Health Initiative.
● Lower proteins C and S, and higher D-dimer were related to thrombosis risk.
● The 25% of women with high D-dimer had a six-times greater risk of thrombosis with hormones.
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Race/ethnicity was self- reported using a list and categorized as 
black or white/other. Body mass index (BMI) was measured to define 
overweight (BMI 25- 30 kg/m2) and obesity (BMI >30 kg/m2).
2.2 | Events ascertainment
Participants were queried every 6 months for possible VT. Hospital 
discharge summaries were reviewed at each clinical center for all 
overnight hospitalizations except selected elective procedures. 
Outpatient- treated VT events were ascertained starting in 1999 by 
investigating self- reports of participants. Validation of potential VT 
events was done as previously described.9 Validated deep vein throm-
bosis (DVT) was based on a physician diagnosis and positive findings 
on doppler or duplex ultrasound, or rarely venogram, plethysmogra-
phy, isotope scan, or at autopsy. Validated pulmonary embolism (PE) 
was based on a discharge summary diagnosis of PE and positive find-
ings on ventilation- perfusion lung scan, pulmonary angiogram, com-
puted tomography, or at autopsy.
2.3 | Nested case control study
Among all trial participants, excluding baseline warfarin users, a 
nested case control study of biomarkers in relation to VT, stroke, 
and myocardial infarction occurring between randomization and 
February 28, 2001 was conducted. One control was selected for 
each case with matching on age, randomization date and prevalent 
vascular disease (myocardial infarction, stroke, or VT). In this study 
we utilized data from the 215 VT cases and all selected controls (867 
total controls).
2.4 | Laboratory analysis
Baseline and follow- up blood samples were analyzed in cases 
and controls using the following methods: fibrinogen (clot- rate 
assay, STA- R instrument, Diagnostica Stago, Parsippany, NJ, 
USA), factor VIII and IX activity (clotting time on mixing with 
factor VIII or IX deficient plasma using STA- Deficient VIII or IX; 
Characteristic, mean or 
frequency
Venous Thrombosis Cases 
(n = 215)
Controls  
(n = 867)
Na
Geometric Mean 
(SD) or % Na
Geometric Mean 
(SD) or %
HT assigned 215 67% 867 52%
Age 215 66.4 (6.6) 867 66.8 (6.7)
Race, % white 215 87% 867 83%
BMI, kg/m2 214 31.3 (6) 862 28.6 (5.7)
Prebaseline VT, % 215 4% 867 2%
Procoagulant factors
Prothrombin Ag, ug/ml 204 107 (18) 838 107 (18)
Factor VIII, % 214 107 (54) 863 97 (49)
Factor IX, % 213 127 (37) 858 128 (37)
von Willebrand Factor, % 212 105 (47) 862 90 (42)
Fibrinogen, g/L 214 3.02 (0.87) 864 2.98 (0.86)
D- dimer, mg/L 212 0.50 (0.36) 864 0.32 (0.27)
Fragment 1.2, nmol/L 192 1.43 (0.42) 760 1.30 (0.38)
Anticoagulant factors
Protein C, % 146 106 (19) 611 110 (20)
Protein S total, % 146 105 (18) 609 107 (18)
Protein S free, % 145 97 (23) 605 101 (20)
Antithrombin, % 209 86 (15) 837 90 (21)
Fibrinolytic factors
PAI- 1 Ag, ng/mL 149 24.9 (18.9) 600 26.6 (17.9)
PAP, nmol/L 200 4.74 (2.20) 805 4.48 (1.76)
Inflammation factor
C- reactive protein, mg/L 209 2.90 (2.80) 838 2.17 (2.26)
BMI, body mass index; HT, hormone therapy; PAI- 1, plasminogen activator inhibitor- 1; PAP, plasmin 
antiplasmin complex; SD, standard deviation; VT, venous thrombosis.
aSample size varied due to availability of plasma for the study.
TABLE  1 Baseline characteristics by 
case- control status
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STA- R instrument, Diagnostica Stago), von Willebrand factor, 
antithrombin and D- dimer (immunoturbidometric or colorimet-
ric assays, Liatest von Willebrand factor, Liatest D- Di, Stachrom 
ATIII; STA- R instrument, Diagnostica Stago), PAI- 1, PAP and 
prothrombin antigen (in- house immunoassays),12,13 prothrombin 
fragment 1.2 (ELISA, Dade Behring, Marburg, Germany), protein 
C antigen, free and total protein S antigen (Asserachrom ELISA, 
Diagnostica Stago), CRP (nephelometry, N High Sensitivity CRP, 
Dade- Behring, Deerfield, IL, USA). Distributions of each bio-
marker were examined blind to case control status. Analytical 
outliers were defined based on knowledge of the biology and ex-
cluded from analysis as follows: factor VIIIc or prothrombin an-
tigen <10%, fragment 1.2 > 7.2 nmol/L (>3 SD above the mean), 
PAI- 1 > 70 ng/mL.14
2.5 | Statistical analysis
Data from both trials were combined for primary analysis. 
Separate analyses by trial were completed secondarily. For base-
line biomarkers in cases and controls, skewed distributions were 
log- transformed to achieve a normal distribution and geomet-
ric means were reported. Hormone therapy use was based on 
intention- to- treat.
Logistic regression, adjusting for age, race, BMI, treatment assign-
ment, pre- baseline self- reported VT, and hysterectomy status, was 
used to determine odds ratios of VT for abnormal levels of each bio-
marker compared to normal levels. Cutoff levels for most biomarkers 
were defined a priori based on the literature with values shown in the 
footnote to Table 1. For the following biomarkers, since there is no ev-
idence on VT to suggest cutoffs for abnormal values a priori, we se-
lected the following cutoffs: fragment 1.2 and PAI- 1 > 90th percentile, 
and for antithrombin, protein C and free and total protein S values less 
than the 5th percentile. Assessments for linear association were also 
made using each biomarker or its log transformed distribution treated 
as a continuous variable. We determined the association of each wom-
an’s number of abnormal biomarkers with VT risk, including previously 
published data for factor V Leiden.1,2
The additive risk of VT with abnormal biomarkers and HT was 
assessed by cross- classifying women by treatment assignment and 
whether they had an abnormal level of each biomarker. Odds ratios 
were determined by logistic regression adjusted for age, race, and 
BMI, with women having normal levels of each biomarker and as-
signed to placebo comprising the reference group. Multiplicative in-
teraction terms between HT assignment and each biomarker were also 
evaluated.
Evaluation of the association of one- year change in biomarkers 
with VT risk required exclusion of 83 women with VT between the 
two phlebotomies. We calculated change in each biomarker by sub-
tracting the baseline from one- year values. Change was divided into 
quartiles with the lowest quartile including those that decreased the 
most and the top quartile those that increased the most. Logistic 
regression was used to analyze the association of quartiles of change 
in biomarkers, and the change values as continuous variables, with 
subsequent VT.
To examine change in biomarker levels in HT compared to pla-
cebo recipients, linear regression was used comparing treatment 
groups, adjusting for age, race, BMI, pre- baseline VT, and hysterec-
tomy status.
3  | RESULTS
With mean follow up of 4.1 years, 215 women had VT, 69 in the 
E trial and 146 in the larger E+P trial. There were 359 and 508 
controls selected in each trial. Among cases, 59% in the E trial and 
54% in the E+P trial had DVT without PE, with the remainder hav-
ing PE. There were 132 women with VT after the one- year follow 
up phlebotomy.
TABLE  2 Odds ratio (95% CI) of VT by categories of baseline 
biomarkersa
Odds Ratiob (95% CI)
Procoagulant factors
Prothrombin >P90, ug/mL 0.6 (0.4, 1.2)
Factor VIIIc > P75, % 1.3 (0.9, 1.9)
Factor IXc >P90, % 0.9 (0.5, 1.5)
von Willebrand factor >P75, % 1.3 (0.9, 1.9)
Fibrinogen >P90, mg/dL 0.7 (0.4, 1.2)
D- dimer >P75, ug/mL 2.8 (2.0, 4.0)
Fragment 1.2 > P90, nmol/L 1.9 (1.2, 3.1)
Anticoagulant factors
Protein C <P5, % 1.8 (0.9, 3.8)
Total protein S <P5, % 1.9 (0.9, 4.1)
Free protein S <P5, % 3.2 (1.6, 6.2)
Antithrombin <P5, % 1.7 (0.9, 3.2)
Fibrinolytic factors
PAI- 1 > P90, ng/ml 0.9 (0.5, 1.7)
PAP >P90, nmol/L 2.4 (1.5, 3.8)
Inflammation factor
C- reactive protein >P75, mg/L 1.2 (0.8, 1.7)
Number of abnormal biomarkers
0- 1 1.0 (ref)
2- 3 2.9 (2.0, 4.3)
4+ 7.8 (1.7, 35.1)
BMI, body mass index; CI, confidence interval; P, percentile; PAI- 1, plas-
minogen activator inhibitor- 1; PAP, plasmin antiplasmin complex; VT, ve-
nous thrombosis.
aCutoff values: prothrombin >137 ug/mL, factor VIIIc >150%, factor IXc 
>172%, vWF >140%, fibrinogen >4.17 g/L, D- dimer >0.54 mg/L, 
F1 + 2 > 1.76 nM, protein C < 84%, total protein S < 83%, free protein 
S < 75%, antithrombin <67%, TAFI >7.53, PAI- 1 > 57.7 ng/ml, PAP 
>7.5 ng/ml, CRP >4.74 mg/L.
bAdjusted for age, race, BMI, treatment assignment, self- reported VT, 
and hysterectomy at screening.
314  |     CUSHMAN et Al.
3.1 | Baseline characteristics
Table 2 shows baseline characteristics by case- control status. Few 
women had pre- baseline self- reported VT. Cases had higher mean 
BMI, higher prevalence of pre- baseline VT, and higher mean baseline 
levels of factor VIII, von Willebrand factor, D- dimer, fragment 1.2, 
and CRP than controls and slightly lower protein C, antithrombin and 
free protein S. These differences were similar considering the trials 
separately, but in the E+P trial, cases had similar free protein S levels 
as controls.
3.2 | Associations of biomarkers with VT
Table 1 shows the odds ratios of VT for abnormal biomarkers, ad-
justed for age, race, BMI, pre- baseline VT, treatment assignment, and 
hysterectomy status. High levels of D- dimer, fragment 1.2 and PAP, 
and low free protein S were significantly associated with increased 
risk of VT with adjusted odds ratios between 1.9 and 2.8. Four fac-
tors were only associated with risk when considered as continuous 
variables (all P < .05). Specifically, for these the adjusted odds ratios 
per 1 SD higher value were: factor VIII (1.2; 95% CI 1.03- 1.4), von 
Willebrand factor (1.3; 95% CI 1.1- 1.5), total protein S (0.8; 95% CI 
0.7- 0.98), and antithrombin (0.8; 95% CI 0.7- 0.98). Considering fac-
tor V Leiden and binary terms for abnormal D- dimer, F1- 2, protein 
C, total protein S, free S, antithrombin, PAP, women with increasing 
numbers of abnormal biomarkers had a higher risk of VT.
When the activation markers D- dimer, F1.2 and PAP were in-
cluded together in the same model, the odds ratios of VT for each of 
these were 2.7 (95% CI 1.9- 4.0), 1.6 (95% CI 1.0- 2.6) and 2.1 (95% CI 
1.3- 3.5), respectively.
None of the above results differed materially comparing the two 
trials (data not shown).
3.3 | Joint associations of HT and abnormal 
biomarkers with VT
To evaluate whether abnormal biomarkers were susceptibility 
factors for HT- related VT, women were cross- classified by treat-
ment assignment and whether they had an abnormal biomarker 
and odds ratios for VT calculated for exposed groups compared to 
women randomized to placebo with a normal biomarker (Table 3). 
In general, HT in the absence of an abnormal biomarker was as-
sociated with a 2- 2.5- fold increased risk of VT, while women with 
abnormal biomarkers assigned to placebo had a 1.0- to 6.5- fold in-
creased risk. Women with the combination of HT plus an abnormal 
biomarker had consistent elevated risks for VT (OR 2.4- 6.0) with 
the largest odds ratio seen for the combination of HT and high 
D- dimer at 6.0 (95% CI 3.6- 9.8). The odds ratios associated with 
the combination of HT plus elevated factor VIII or von Willebrand 
factor, or lower total protein S or antithrombin were approxi-
mately additive, while the odds ratios for the combination of HT 
and elevated fragment 1.2, PAP, CRP, free protein S, and low pro-
tein C were less than additive. There were no material differences 
between the two trials in these results (data not shown). Despite 
the elevated risk of HT plus abnormal biomarkers, tests for multi-
plicative interaction between HT assignment and each biomarker 
as a continuous or binary variable revealed no statistically signifi-
cant multiplicative interactions (all P > .05).
To evaluate a multi- marker score considering eight biomarkers 
associated with VT risk (factor V Leiden and binary terms for ab-
normal D- dimer, F1- 2, protein C, total protein S, free protein S, an-
tithrombin, and PAP), women were classified as having 0- 1, 2, or 3+ 
abnormal factors. In the figure, compared to women with 0- 1 abnor-
mal factors assigned to placebo, the odds ratio of VT with 2 or 3+ 
abnormal factors rose progressively such that women assigned to 
HT who had 3+ abnormal factors had 15.5- fold increased odds of VT 
(95% CI 6.8- 35.1) adjusting for age, race, BMI, pre- baseline VT, and 
hysterectomy status.
3.4 | Change in biomarkers
The one- year changes in biomarkers in each trial by case- control 
status, excluding women who had VT in that year, are shown in 
Supplemental Table A. In the E trial all factors changed similarly in 
cases and controls (all P > .15) except von Willebrand factor, which 
rose more among cases than controls (11 vs 1%, P = .05). In the E+P 
trial factor VIIIc and fragment 1.2 rose more in cases than in controls 
(factor VIII 10 vs. 0%, P = .02, fragment 1.2, 0.32 vs. 0.09 nmol/L, 
P = .04; for all other factors P > .15).
One- year changes in biomarkers with treatment compared to 
placebo were generally similar for E and E+P (Supplemental Table B). 
In the combined trials, fibrinogen, PAI- 1 and antithrombin declined 
with HT compared to placebo while PAP and CRP increased and the 
other factors did not change.
Table 4 shows associations of quartiles of change in biomarkers 
with odds of VT after the second blood collection. Compared to 
women in the first quartile of change in each biomarker, women in 
the top quartile of change in prothrombin, factor VIII, von Willebrand 
factor, fragment 1.2, PAP, and CRP were at increased risk of subse-
quent VT. While the 95% confidence intervals for these odds ratios 
all included 1.0, PAP and CRP change in the top compared to bottom 
quartile were associated with a 1.9- fold increased risk. Considering 
the biomarkers as continuous variables, only larger increases in fac-
tor VIII were associated with subsequent VT; the odds ratio of VT for 
a 32% greater one- year increase of factor VIII (1 SD increment) was 
1.3 (95% CI 1.1- 1.6). Interpretation of results did not differ materially 
considering the trials separately (data not shown).
4  | DISCUSSION
4.1 | Main findings
In this study some thrombosis biomarkers were susceptibility fac-
tors for HT- associated VT, especially higher baseline D- dimer, which 
was associated with 6- fold increased odds of VT with HT. This risk 
increase is comparable to that of the combination of factor V Leiden 
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and HT previously reported in these trials.1,2 In the presence of three 
or more of eight VT risk factors in combination with HT, the odds 
ratio of VT was substantially higher at 15.5. One- year change in bio-
markers with HT was not robustly associated with subsequent VT 
risk, although modest associations were seen for factor VIII, PAP, 
and C- reactive protein. New findings regarding risk factors for VT 
include associations of higher levels of prothrombin fragment 1.2 
and PAP with VT risk (although prothrombin fragment 1.2 has been 
reported in relation to VT risk in cancer patients).15
4.2 | Relation to other work
Venous thrombosis is a common serious vascular complication 
of menopausal HT and limited studies suggest the risk is higher in 
women who are older, obese or have factor V Leiden, prothrombin 
20210A or non- O blood group.1,2,16–19 In contrast to literature for 
oral contraceptives, despite many studies on effects of HT on he-
mostasis factors,7 we are aware of no other prospective studies on 
biomarkers related to VT risk (or their changes on treatment) as pre-
disposing factors for HT- related VT.
4.3 | Potential implications of the findings
Among the biomarkers considered here, D- dimer was most strongly 
related to VT. Women with D- dimer >0.54 mg/L (top quartile) had 
nearly a three- fold higher risk of future VT than women in the lowest 
quartile. While much clinical interest has focused on D- dimer in pre-
dicting recurrent VT,20–22 our findings confirm prior publications on 
D- dimer and risk of first VT in men and women.23–25 Further, women 
with elevated D- dimer randomized to HT were at six- fold increased 
risk compared to women with lower D- dimer on placebo. In the WHI 
trials, baseline D- dimer was also associated with increased risk of 
TABLE  3 Odds ratio (95% CI) of VT by baseline biomarkers and  
treatment assignmenta
Odds 
Ratio (95% CI)
Factor VIIIc P75, %
Normal, Placebo 1.0 (ref)
Normal, HT 1.9 (1.3, 2.7)
Elevated, Placebo 1.0 (0.5, 1.9)
Elevated, HT 2.7 (1.7, 4.5)
von Willebrand factor >P75, %
Normal, Placebo 1.0 (ref)
Normal, HT 1.9 (1.3, 2.7)
Elevated, Placebo 1.0 (0.5, 2.1)
Elevated, HT 2.7 (1.7, 4.5)
D- dimer >P75, ug/ml
Normal, Placebo 1.0 (ref)
Normal, HT 2.1 (1.4, 3.3)
Elevated, Placebo 2.8 (1.6, 4.9)
Elevated, HT 6.0 (3.6, 9.8)
Fragment 1.2 > P90, nmol/L
Normal, Placebo 1.0 (ref)
Normal, HT 2.4 (1.6,3.5)
Elevated, Placebo 2.7 (1.3, 5.9)
Elevated, HT 3.9 (2.1, 7.2)
PAP >P90, nmol/L
Normal, Placebo 1.0 (ref)
Normal, HT 2.5 (1.7, 3.6)
Elevated, Placebo 3.3 (1.6, 6.7)
Elevated, HT 4.9 (2.6, 9.3)
Protein C <P5, %
Normal, Placebo 1.0 (ref)
Normal, HT 2.4 (1.6, 3.7)
Reduced, Placebo 3.3 (1.1, 10.1)
Reduced, HT 3.2 (1.2, 8.3)
Total protein S <P5, %
Normal, Placebo 1.0 (ref)
Normal, HT 2.3 (1.5, 3.5)
Reduced, Placebo 2.0 (0.7, 5.9)
Reduced, HT 4.3 (1.5, 12.3)
Free protein S <P5, %
Normal, Placebo 1.0 (ref)
Normal, HT 2.6 (1.7, 4.0)
Reduced, Placebo 6.5 (2.3, 17.8)
Reduced, HT 5.1 (2.0, 12.6)
Antithrombin <P5, %
Normal, Placebo 1.0 (ref)
Normal, HT 2.1 (1.5, 2.9)
Odds 
Ratio (95% CI)
Reduced, Placebo 1.4 (0.4, 5.3)
Reduced, HT 3.8 (1.8, 7.9)
C- reactive protein >P75, mg/L
Normal, Placebo 1.0 (ref)
Normal, HT 1.9 (1.3, 2.9)
Elevated, Placebo 1.0 (0.6, 1.9)
Elevated, HT 2.4 (1.5, 3.9)
BMI, body mass index; CI, confidence interval; HT, hormone therapy; P, 
percentile; PAP, plasmin antiplasmin complex; VT, venous thrombosis.
aWomen were cross classified for their level of each hemostatic factor 
(cutoffs provided in Table 2 footnote) and treatment assignment, and 
each group was compared using logistic regression models to those ran-
domized to placebo and who had normal levels of each factor. Models 
were adjusted for age, race, BMI, treatment assignment, self- reported 
VT, and hysterectomy status at screening. P- values for multiplicative in-
teraction between treatment assignment and abnormal biomarkers were 
all >.05.
(Continues)
TABLE  3  (Continued)
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stroke and coronary heart disease and, among a variety of biomark-
ers, only the change in D- dimer with HT predicted stroke risk (but 
not coronary risk) during follow- up.26,27
Considering possible clinical application of D- dimer testing, the 
threshold value defining VT risk in this study is similar to the thresh-
old used to rule out acute VT with this assay (0.50 mg/L), and that 
which has been proposed for clinical use in determining a group at 
low risk of recurrent VT after completing a course of anticoagulation 
for first unprovoked VT.20,21 Based on our definition of elevated D- 
dimer, 25% of women considering HT could be identified as having 
an increased risk based on D- dimer, with an estimated five- year cu-
mulative incidence of VT of 6% with HT (assuming an annual rate 
without treatment and with normal D- dimer of 2 per 1000). If HT 
were withheld from women with elevated D- dimer, their five- year 
cumulative incidence of VT would be reduced to 3%. The number 
needed to test to prevent one VT over five years of treatment would 
then be 33 (1/0.03). Free protein S and PAP had similar odds ratios 
for VT as D- dimer in combination with HT use, but these point es-
timates were not precise (wide CIs) and the threshold defining ab-
normal values would only identify 5- 10% of women at risk so the 
number needed to screen would be much higher. Similarly, consider-
ing a multi- marker approach (Figure 1) among women with three or 
more abnormal biomarkers there was an incremental increase in the 
odds ratio of VT to 15.5, but only 3% of non- cases had three or more 
abnormal biomarkers.
We are unaware of previous studies in healthy people demon-
strating associations of higher levels of PAP and prothrombin frag-
ment 1.2 with risk of future VT. In the Longitudinal Investigation of 
Thromboembolism Etiology, elevated PAP was not associated with 
VT risk.28 Plasmin antiplasmin is formed upon plasmin generation, 
thus it is a marker of the fibrinolytic response to fibrin formation. 
Plasmin antiplasmin increases with HT.29 Fragment 1.2 is liberated 
upon conversion of prothrombin to thrombin and indicates en-
hanced procoagulant activity. It has variably been reported to in-
crease with HT treatment.29 Because these factors are affected by 
HT and this study was by design enriched with HT users, further 
TABLE  4 Odds ratio (95% CI) of VT after Year 1 by one- year 
change in biomarkers
Odds 
Ratio (95% CI) P Valuea
Prothrombin, ug/ml .12
Q1 < −9.2) 1.0 (ref)
Q2 (−9.2 to 1.2) 0.8 (0.4, 1.6)
Q3 (−1.2 to 7.9) 1.3 (0.7, 2.3)
Q4 (>7.9) 1.5 (0.9, 2.7)
Factor VIIIc, % .01
Q1 (<−12.9) 1.0 (ref)
Q2 (−12.9 to 0) 0.8 (0.5, 1.5)
Q3 (0.1 to 16) 0.9 (0.5, 1.7)
Q4 (>16) 1.4 (0.8, 2.4)
von Willebrand factor, % .13
Q1 (<−16.9) 1.0 (ref)
Q2 (−16.9 to 0) 0.8 (0.5, 1.5)
Q3 (0.1 to 16) 1.2 (0.7, 2.1)
Q4 (>16) 1.4 (0.8, 2.4)
Fibrinogen, g/L .59
Q1 (<−0.51) 1.0 (ref)
Q2 (−0.51 to 0.14) 0.6 (0.4, 1.1)
Q3 (−0.13 to 0.29) 0.9 (0.5, 1.5)
Q4 (>0.30) 0.9 (0.6, 1.6)
D- dimer, ug/ml .32
Q1 (<−0.07) 1.0 (ref)
Q2 (−0.07 to 0.02) 0.5 (0.3, 1.0)
Q3 (0.03 to 0.17) 0.7 (0.4, 1.3)
Q4 (>0.17) 1.1 (0.6, 1.8)
Fragment 1.2, nmol/L .27
Q1 (<−0.10) 1.0 (ref)
Q2 (−0.10 to 0.07) 0.7 (0.4, 1.4)
Q3 (0.08 to 0.24) 0.7 (0.3, 1.3)
Q4 (>0.24) 1.3 (0.7, 2.3)
Antithrombin, % .87
Q1 (<−11.9) 1.0 (0.5, 1.8)
Q2 (−11.9 to 4) 1.0 (0.6, 1.9)
Q3 (−3.9 to 5.0) 0.9 (0.5, 1.6)
Q4 (>5.0) 1.0 (ref)
PAI- 1, ng/ml .40
Q1 (<−12.6) 1.0 (ref)
Q2 (−12.6 to 3.9) 0.8 (0.4, 1.5)
Q3 (−3.9 to 4.5) 0.9 (0.4, 1.7)
Q4 (>4.5) 0.8 (0.4, 1.5)
PAP, nmol/L .17
Q1 (<−0.28) 1.0 (ref)
Q2 (−0.28 to 0.44) 1.3 (0.7, 2.5)
Q3 (0.45 to 1.19) 1.0 (0.5, 2.0)
Odds 
Ratio (95% CI)
 P 
Valuea
Q4 (>1.19) 1.9 (1.0, 3.5)
C- reactive protein, mg/L .49
Q1 (<−0.35) 1.0 (ref)
Q2 (−0.35 to 0.46) 1.1 (0.6, 2.2)
Q3 (0.47 to 2.54) 1.7 (0.9, 3.1)
Q4 (>2.54) 1.9 (1.0, 3.4)
BMI, body mass index; CI, confidence interval; PAI- 1, plasminogen acti-
vator inhibitor- 1; PAP, plasmin antiplasmin complex; Q, quartile; VT, ve-
nous thrombosis.
aP value from a logistic regression model modeling VT by continuous 1- 
year difference in biomarker level. All models adjusted for age, race, BMI, 
treatment assignment, self- reported VT, and hysterectomy status at 
screening.
TABLE  4  (Continued)
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study of their relationships with VT risk in healthy populations is in-
dicated. Similar to another study,30 we were unable to confirm previ-
ous findings that higher factor IX is a VT risk factor.31,32 We also did 
not confirm prior conflicting reports of an association of PAI- 1 with 
VT risk.28,33 Lack of association of well- established VT risk factors, 
higher factor VIIIc and von Willebrand factor with odds of VT here 
was unexplained, and these were associated with stroke and coro-
nary risk in our study.26,27
4.4 | Study limitations
Limitations of this study require consideration. Participants were 
older than women who would currently be considering starting 
HT. There was some nonadherence to assigned treatment in both 
placebo and HT groups,11 although this was less early in the trial 
when most of our cases occurred. If anything, the impact of nonad-
herence would most likely bias our findings to the null, making our 
estimates of interaction of biomarkers with HT underestimates and 
thus conservative. We had limited power to analyze data by HT type, 
however most associations were similar by study. Studies suggest a 
lower risk of VT with estradiol or transdermal treatment than oral 
conjugated equine estrogens34,35 and we could not address this. To 
conserve power, we did not exclude women with pre- baseline self- 
reported VT, but we did adjust for this. Use of ELISAs for proteins 
C and S would miss functional deficiencies that might have clinical 
relevance but would be rare. Due to concern for type I error, we did 
not study nonlinear associations of biomarkers with VT nor did we 
explore other thresholds (besides our a priori defined ones) to define 
abnormal values of biomarkers. Assessment of change in hemostatic 
factors in relation to VT risk was limited because we necessarily ex-
cluded VT cases occurring in the first year of follow- up, between the 
two blood collections. It would have been preferable if the second 
phlebotomy had been done four to six weeks after randomization to 
increase the opportunity to relate changes in biomarkers to VT risk. 
Finally, we did not measure change in protein S. Given our findings 
for risk of VT with HT plus low baseline protein S, this might be ex-
plored in future studies.
4.5 | Study strengths
The key strength of the study was the evaluation of participants 
from a rigorously conducted randomized controlled trial, eliminat-
ing selective prescribing of HT. In addition, we used baseline blood 
samples prior to HT use or VT for measurement of biomarkers. We 
are not aware of an existing or planned study with similar design that 
could be used for replication or which might overcome the limita-
tions mentioned above.
5  | CONCLUSIONS
The WHI clinical trials provided a unique opportunity to examine 
associations of biomarkers of interest with VT, determine suscepti-
bility factors for HT- associated VT, and determine if changes in bio-
markers with HT are related to the incidence of VT. Findings here 
support potential for clinical use of D- dimer testing in advance of 
HT prescription to identify women at increased risk of VT. Further 
study of a multi- marker score in selected high- risk populations might 
be useful.
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F IGURE  1 Association of Number of Risk Factors with Risk 
of Future Venous Thrombosis (VT), Stratified by Treatment 
Assignment. Combining both trials, women were cross classified by 
treatment assignment and their number of risk factors (including 
those associated with VT in Table 1 and factor V Leiden). The 
reference group was women with 0- 1 risk factors assigned to 
placebo. Analyses were adjusted for age, race, BMI, pre- baseline 
VT, and hysterectomy status
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